Superworth

Opus Genetics profit margin IRD

Gross, operating and net profit as a share of revenue over the last twelve months, from 2022.

Net margin, 12 months
n/m
not a meaningful number
Peer median
11.2%

Opus Genetics' net margin works out at −1092% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY2025n/an/a
FY2024n/an/a
FY2023−52.4%−55.5%
FY202244.9%45.7%
FY2021n/an/a
FY2020n/an/a
FY2019n/an/a
FY2018n/an/a
FY2017n/an/a
FY2016n/an/a
FY2015n/an/a
FY2014n/an/a
FY2013n/an/a
FY2012n/an/a
FY2011n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26n/an/an/a
Q1 FY26n/an/an/a
Q4 FY25n/an/an/a
Q3 FY25n/an/an/a
Q2 FY25n/an/an/a
Q1 FY25n/an/an/a
Q4 FY24n/an/an/a
Q3 FY24n/an/an/a
Q2 FY24−85.7%−127.0 pts−91.7%
Q1 FY24−59.4%−104.4 pts−63.9%
Q4 FY23−52.4%−97.3 pts−55.5%
Q3 FY2350.3%n/a50.8%

Against its peers

Companies in Drug Manufacturers - General nearest Opus Genetics' size, closest first, today.

CompanyProfit margin
IRDOpus Geneticsn/m
NATRNatures Sunshine Products3.7%
ARVNArvinas2.9%
PBYIPuma Biotechnology11.6%
IRWDIronwood Pharmaceuticals33.4%
ZVRAZevra Therapeutics42.8%
CRMDCorMedix40.5%
COLLCollegium Pharmaceutical5.9%
ABUSArbutus Biopharma84.2%
AMPHAmphastar Pharmaceuticals10.8%
LFVNLifevantage2.8%
Peer median11.2%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Opus Genetics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.